Translate Bio Announces Timing of Interim Results from mRNA Therapeutic Clinical Trial in Patients with Cystic Fibrosis; Data Expected in Early Q2 2021
07. Januar 2021 07:30 ET
|
Translate Bio, Inc.
-- MRT5005 is the first clinical-stage mRNA therapeutic with nebulized delivery to the lung and first to be administered in multiple doses for the treatment of a chronic genetic disease -- --...
Translate Bio Highlights mRNA Platform Potential for the Treatment of Cystic Fibrosis (CF) at the 34th Annual North American Cystic Fibrosis Conference
07. Oktober 2020 16:05 ET
|
Translate Bio, Inc.
-- Lead candidate MRT5005 leverages Translate Bio’s proprietary LNP and mRNA platform and is the only clinical-stage mRNA therapeutic in development for the treatment of CF -- -- Second CF program,...
Translate Bio to Participate in Upcoming Investor Conferences
29. September 2020 16:05 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Resumes Enrollment and Dosing in Phase 1/2 Clinical Trial of MRT5005 in Cystic Fibrosis
08. September 2020 07:30 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
07. Mai 2020 16:26 ET
|
Translate Bio, Inc.
-- Pursuing development of mRNA vaccine against COVID-19 through expanded collaboration with Sanofi Pasteur -- -- Existing large-scale manufacturing capacity expected to help meet needs of...
Translate Bio Provides MRT5005 Program Updates
26. März 2020 16:30 ET
|
Translate Bio, Inc.
-- FDA grants Rare Pediatric Disease designation for MRT5005 for treatment of cystic fibrosis – -- Response to COVID-19 pandemic anticipated to cause interruptions in certain clinical trial...
Bombardier gewinnt Auftrag zur Lieferung von 396 MOVIA U-Bahn-Wägen für Singapurs Nord-Süd- und Ost-West-Verbindungen
26. Juli 2018 05:20 ET
|
Bombardier Transportation
Mit 396 neuen Wägen steigt die Zahl MOVIA Fahrzeuge in Singapur auf 672, wodurch diese U-Bahn-Flotte eine der größten von Bombardier weltweit wirdU-Bahn-Wägen decken eine Gesamtstrecke von 102 km und...
Bombardier décroche un contrat pour fournir 396 voitures de métro MOVIA destinées aux lignes nord-sud et est-ouest de Singapour
26. Juli 2018 05:20 ET
|
Bombardier Transport
Nouvelle commande de 396 voitures de métro portant le nombre de véhicules MOVIA à Singapour à 672, ce qui en fait l'une des plus grandes flottes de métro de Bombardier au mondeLes deux lignes Mass...
Bombardier Wins Contract to Provide 396 MOVIA Metro Cars for Singapore’s North-South and East-West Lines
26. Juli 2018 05:20 ET
|
Bombardier Transportation
New order of 396 metro cars bring the number of MOVIA vehicles in Singapore to 672, making it one of Bombardier’s largest metro fleet in the world The two high-capacity Mass Rapid Transit (MRT) lines...